INTRODUCTION
Vascular smooth muscle cell (VSMC) proliferation contributes to the arterial remodeling that occurs in hypertension (Intengan et al., 2001) . Indeed, VSMC from hypertensive rats (SHR) proliferate faster than normotensive rats (Wistar-Kyoto rats; WKY) (Resink, 1987) . This phenomenon has been attributed to differences in cell cycle regulation in SHR and WKY (Tanner et al., 2003) . Mammalian cell proliferation is governed by the cell cycle (Sherr, 1996) . Cell cycle progression is a tightly controlled event regulated positively by cyclin-dependent kinases (CDK) and their cyclinregulatory subunits (Sherr CJ, 1993) , and negatively by CDK inhibitors and tumor suppressor genes (Hunter, 1993) .
Aprotinin is a broad-spectrum serine protease inhibitor with a molecular weight of 6512 d. It is widely used in congenital cardiac surgery for its hemostatic and anti-inflammatory benefits (Westaby, 1993; Levy, 2001) , although its safety when used in adults undergoing coronary artery surgery has been questioned (Mangano et al., 2006) . We previously found that aprotinin inhibited VSMC inflammation and proliferation via induction of heme oxygenase (HO)-1 . Expression of HO-1 in blood vessels by hemin treatment in vivo reduces vasoconstriction and normalizes blood pressure in SHR (Ndisang et al., 2002; Wang et al., 2006) . Similarly, HO inhibitors increase blood pressure and peripheral resistance, suggesting a critical vasoregulatory role for HO (Ndisang et al., 2003) . Interestingly, induction of HO-1 by chronic hemin treatment of SHR inhibits proliferation of VSMC (Chang et al., 2008) . We previously observed that induction of HO-1 by hemin inhibited proliferation of VSMC through the regulation of cell cycle arrest in SHR (Jeon et al., 2009) . Thus genetic approaches targeting HO-1 or pharmacological interventions using HO-1 inducers may offer a promising therapeutic modality in the treatment of hypertension.
Based on these ideas, we investigated the effects of aprotinin on VSMC proliferation. Here, we have shown that aprotinin inhibits VSMC proliferation of SHR and induces G1/G0 cell arrest through regulation of cyclin D and p21 via the induction of HO-1.
METHODS

Reagents
Cell culture reagents were purchased from Hyclone. Acrylamide and Western blot reagents were purchased from Bio-Rad. Cell cycle regulator antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA), and Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The antibody against HO-1 was purchased from Stressgen Bioreagents (Victoria, BC, Canada). Tin protoporphyrine IX (SnPPIX) was purchased from Calbiochem (La Jolla, CA, USA). Lipofectamine 2000 was purchased from R&D Systems (Minneapolis, MN, USA). PRO-PREP protein extract solution was purchased from iNtRON Biotechnology (Sungnam, Korea). All other chemicals, including aprotinin, 3-(4,5 dimethylthiazole 2yl)-2,5-diphenyl tetrazolium bromide thiazoyl blue (MTT), propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Rats
Specific pathogen-free male inbred WKY and SHR, 12 to 16 weeks of age, were purchased from Japan SLC Inc. (Shizuoka, Japan). All experimental animals received autoclaved food and bedding to minimize exposure to viral or microbial pathogens. The rats were cared for in accordance with the Guide for the Care and Use of Experimental Animals of Yeungnam Medical Center.
Cell culture
Rats were anesthetized by pentobarbital (50 mg/kg). Thoracic aortas were isolated and connective tissues were removed. VSMC were processed using a 1 mm chop setting in a 10 cm culture dish, and cultured with DMEM containing 50% fetal bovine serum (FBS) and 1% antibiotics (penicillin 10,000 U/ml, streptomycin 10,000 μl/ml) and were incubated in a CO2 incubator (95% CO2, 5% O2, 37 o C) for 7 days. Cells from passage 4 to 10 were used for the experiments.
Cell proliferation
To measure proliferation, VSMC from SHR and WKY were seeded at 10×10 4 cell/ml. Cell numbers were determined with a hemocytometer after 0, 1, 2, and 3 days in response to stimulation with 10% FBS. Cell proliferation was also analyzed using the MTT assay. VSMC were seeded on 24 well plates (1×10 4 cells/well) and cultured for 3 days in DMEM containing 10% FBS. VSMC were serum-starved for 48 h and then stimulated with reagents. After different treatments, 50 μl aliquots of 1 mg/ml MTT solution was added to each well (0.1 mg/well) and incubated for 4 h. Supernatants were aspirated, crystals dissolved in 200 μl dimethyl sulfoxide (DMSO), and 100 μl was placed in 96-well plates. Light absorbance at 570 nm was read on a Microplate Reader (Bio-Rad). Experiments were repeated three times, each in triplicate.
Western blot analysis
Cells were lysed in PRO-PREP protein extract solution. The sample was centrifuged at 13,000×g for 5 min at 4 o C. Protein concentrations were determined by the Bradford method. An equal volume of 2× sample buffer was added to aliquots of the supernatant fraction from the lysates and the mix was boiled for 5 min. 30 micrograms of protein were loaded per lane and resolved by 10% SDS-PAGE for 1 hour 30 min at 30 mA. The separated proteins were transferred to PVDF membranes (Millipore) for 1 h at 100 V with a SD Semi-dry Transfer Cell (Bio-Rad). The membranes were blocked with 5% skim milk in 1× PBS containing 0.05% Tween 20 (PBS-T) for 1 h at room temperature. The membranes were then incubated with antibodies against HO-1, cyclin D, p21, and β-actin. Proteins were detected with a horseradish peroxidase-coupled secondary antibody using an ECL system.
FACs analysis
For cell cycle analysis, cells were harvested 48 h after stimulation in the absence or presence of aprotinin (1 μM to 10 μM), washed, then fixed in 95% ethanol overnight at 4 o C, incubated with RNase A (50 μg/ml) for 30 min at 37 o C and then incubated with PI (50 μg/ml) for 30 min at 37 o C. The intracellular PI fluorescence intensity of each 10,000 cells was measured in each sample using a flow cytometer (Becton Dickinson, San Jose, CA).
Transfection of VSM C
VSMC were seeded on 60 mm dishes and cultured in DMEM containing 10% FBS. A day before transfection, 1×10 4 cells in 60 mm plates were incubated in growth medium without antibiotics so that cells were 90∼95% confluent at the time of transfection. Transfection complexes were formed as follows: mouse HO-1 DNA (μg): Lipofectamine 2,000 (μl) ratio from 1：0.5 to 1：2.5. 100 μl of complexes were added to each well containing cells and medium. The cells were then incubated at 37 o C in a CO2 incubator for 3 h.
Statistical analysis
Results are expressed as mean±SEM from at least three independent experiments. For comparison between multiple groups, statistical significance was tested by the MannWhitney test using SPSS version 12.0.
RESULTS
Aprotinin inhibits VSM C proliferation of SHR
First, we confirmed that VSMC from SHR proliferated faster than those of WKY. VSMC were cultured in medium supplemented with aprotinin (1, 5, 10 μM) for 24 h. Aprotinin treatment significantly decreased VSMC proliferation of SHR compared with WKY cells (Fig. 1A) . To confirm these data, we tested VSMC proliferation in medium supplement with aprotinin (10μM) by determining cell numbers over a period of 3 days. Aprotinin treatment significantly decreased cell populations by almost three-fold at 3 days compared with WKY (Fig. 1B) .
Aprotinin inhibits cell cycle progression in VSMC from SHR through HO-1
To understand the underlying mechanism of aprotinin- blocked proliferation, VSMC were serum starved and then stimulated with 10% FBS. Cell cycle progression was examined using PI staining and flow cytometry. After 10% FBS stimulation for 24 h, 47% of VSMC from SHR were at the G1/G0 phase, whereas 58% of VSMC were at the G1/G0 phase in WKY. The remaining cells were in the S or G2/M phase. More VSMC from SHR (77%) were at the G1/G0 boundary compared with WKY (63%) after aprotinin (10 μM) treatment. Aprotinin inhibits proliferation of VSMC through activation of HO-1 ), and we could block this inhibit with the HO-1 inhibitor, SnPPIX (1 μM) (Fig. 2) . These results indicate that aprotinin-induces HO-1 to inhibit VSMC proliferation by slowing down cell cycle progression and arresting cells at the G1/G0 phase in VSMC from SHR.
Aprotinin increases HO-1 and p21 but decreases cyclin D levels in VSM C of SHR
To assess cell cycle arrest, VSMC were growth arrested by serum starvation for 48 h. The basal level of cyclin D in VSMC of SHR was higher than WKY, and downregulated by serum starvation (Fig. 3A) . Cyclin D association with cyclin dependent kinase (CDK)-2, CDK-4, and CDK-6 is important for early G1 progression, and CDK-4 levels were downregulated by serum starvation (Dulic, 1992) . VSMCs from SHR showed higher levels of the CDK inhibitor, p21. We next tested the effect of aprotinin on key downstream regulators of the G1/G0 transition. Aprotinin (10 μM) treatment reduced cyclin D but increased p21 and HO-1 levels in VSMC from SHR (Fig. 3B) . Together, these observations suggest that aprotinin-induced HO-1 could inhibit VSMC proliferation.
Aprotinin inhibited proliferation of VSMC from SHR through HO-1
Aprotinin induced HO-1 inhibited VSMC proliferation after stimulation with 10% FBS. VSMC from SHR proliferated faster than those from WKY, and aprotinin blocked this proliferation (Fig. 4A) . The HO-1 inhibitor, SnPPIX (1 μM) reversed the anti-proliferative effect of aprotinin to a greater extent in SHR than WKY, indicating that HO-1 activity may be different in the two types of rats. To confirm a direct role for HO-1 in VSMC proliferation, we transfected mouse HO-1 DNA into VSMC from SHR. This ectopic HO-1 expression significantly suppressed cell proliferation (Fig. 4B, C) .
DISCUSSION
Aprotinin is a broad-spectrum serine protease inhibitor extracted from bovine lung tissue. It is widely used to reduce blood loss and the need for transfusion after cardiac operations requiring cardiopulmonary bypass (CBP) (Bidstrup et al., 1989) . However, the effects of aprotinin are not uniformly observed and may be due to the aprotinin dose utilized (Englberger et al., 2002) . Although the efficacy of aprotinin as a hemostatic agent is indisputable, its safety has been questioned (Mangano et al., 2006) . Recently, McEvoy and colleagues indicated that clinically relevant aprotinin concentrations in an intact murine model of ischemia reperfusion induces differential effects on left ventricular contractility, cytokine release, and oxidative stress (McEvoy et al., 2008) . Another report demonstrated less postoperative bleeding, blood product transfusion, and early extubation with aprotinin use (Ngaage et al., 2008) . We recently reported that aprotinin reduced iNOS expression, cell proliferation, and reactive oxygen species through inducing HO-1 in VSMC under inflammatory conditions ). Here, we investigated the effect of aprotinin treatment on the growth of VSMC in SHR. We first demonstrated that aprotinin induces G1/G0 arrest but not apoptosis, as measured using the MTT assay and DNA content estimation through FACS analysis. Cell proliferation was decreased by an average of 29% after 4 days of 10 μM aprotinin in VSMC of SHR (Fig. 1B) . Aprotinin treatment significantly increased the fraction of cells in G1/G0 phases (Fig. 2B) , down-regulated cyclin D, and upregulated p21. Interestingly, aprotinin treatment induced HO-1 protein in VSMC from SHR and reduced proliferation (Fig. 3B) , consistent with our previous findings that hemininduced HO-1 expression reduced the proliferation of VSMC of SHR under inflammatory conditions (Jeon et al., 2009) such as hypertension. To confirm the effects of HO-1 directly, we transfected cells with mouse HO-1 DNA to specifically inhibit proliferation (Fig. 4C) . Pretreatment with SnPPIX, an HO-1 inhibitor, blocked the effects of aprotinin on cell proliferation (Fig. 4A ) and cell cycle arrest (Fig. 2B ), while SnPPIX alone had no effect.
Upregulation of p21 protein, HO-1 derived CO, and bilirubin-dependent modulation of ERK1/2 phosphorylation underlie HO-1 mediated inhibition of cell proliferation (Peyton et al., 2002; Taille et al., 2003) . CDK inhibitor negatively regulates cell proliferation (Dong et al., 2004) . Deletion of the p21 gene in mouse VSMC abolished the inhibitory effect of HO-1 on cell proliferation (Duckers et al., 2001) . Consistent with these reports, we found that inhibition of VSMC proliferation by aprotinin was accompanied by an increased expression of p21 protein in SHR only (Fig. 3B) .
In conclusion, aprotinin inhibited VSMC proliferation by decelerating cell cycle progression through arresting cells at G0/G1 phase. The induction of HO-1 mediates the inhibitory effect of aprotinin on cell growth in SHR. Changes in the level of p21 and cyclin D might also be involved in aprotinin-mediated inhibition of VSMC proliferation.
